Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
The ISTH DIC score combines platelet count, D-dimer/fibrin degradation markers, prothrombin time prolongation, and fibrinogen level to diagnose overt DIC in appropriate clinical contexts such as sepsis, trauma, obstetric emergencies, or malignancy. Score ≥5 is compatible with overt DIC (sensitivity 91–93%, specificity 97–98%). Score 3–4 suggests non-overt DIC requiring serial monitoring. The cardinal principle: treat the underlying cause aggressively — DIC cannot be corrected without addressing the precipitating condition. To differentiate DIC from liver disease, check Factor VIII: it is consumed in DIC but normal or elevated in liver failure. Use serial ISTH scores to guide transfusion decisions (FFP, cryoprecipitate, platelets) in actively bleeding DIC patients.
Formula: ISTH DIC score = platelet points + fibrin marker points + PT prolongation points + fibrinogen points. Overt DIC if total ≥5.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
DIC diagnosis requires simultaneous evaluation of four coagulation parameters from a single blood draw. Order a complete coagulation panel: CBC with platelet count, prothrombin time (PT) with reported prolongation in seconds above the upper limit of normal, fibrinogen level (in g/L or mg/dL), and D-dimer or fibrin degradation products (FDPs). Score each component as follows: **Platelet count:** >100 × 10⁹/L = 0 points; 50–100 × 10⁹/L = 1 point; <50 × 10⁹/L = 2 points. Both the absolute platelet count and the rate of fall matter — a rapidly declining platelet count (even if still >100k) is a warning sign. **D-dimer / fibrin degradation products:** No increase = 0 points; moderate increase = 2 points; strong increase = 3 points. 'Moderate' and 'strong' are defined relative to your lab's reference range — typically, >2× the upper limit of normal is moderate and >5–10× upper limit is strong. Elevated D-dimer reflects fibrinolysis of cross-linked fibrin clots, indicating ongoing clot formation and breakdown. **PT prolongation:** <3 seconds above ULN = 0 points; 3–6 seconds = 1 point; >6 seconds = 2 points. PT prolongation reflects consumption of clotting factors (particularly factors I, II, V, VIII, X) as they are consumed in widespread thrombin generation. Early DIC may show only minimal PT changes. **Fibrinogen level:** >1 g/L (100 mg/dL) = 0 points; ≤1 g/L = 1 point. Fibrinogen is consumed in DIC as thrombin converts it to fibrin. However, fibrinogen is also an acute-phase reactant — its baseline may be elevated in inflammatory states, making the absolute value misleading early in DIC.
Sum all four component scores to obtain a total ISTH DIC score (range 0–8). Interpret as follows: **Score ≥5 (overt DIC):** Compatible with overt DIC in the appropriate clinical context (sepsis, trauma, obstetric emergency, disseminated malignancy). Sensitivity 91–93%, specificity 97–98% for overt DIC in validation studies. Management: treat the underlying cause urgently, initiate supportive transfusion therapy for actively bleeding patients, and calculate serial DIC scores every 6–12 hours to monitor treatment response. A rising score despite treatment indicates the underlying cause is not controlled. **Score 3–4 (non-overt or early DIC):** Suggests developing coagulopathy consistent with early or compensated DIC. These patients have partially compensated coagulation activation where factor consumption is balanced by increased production. Serial monitoring every 6–8 hours is essential — a score trending upward (3 → 4 → 5) indicates progression to overt DIC. Repeat coagulation studies and treat the underlying cause aggressively. **Score <3 (unlikely overt DIC):** DIC is unlikely based on current laboratory parameters. If clinical suspicion remains high, repeat labs in 6–12 hours, as DIC can evolve rapidly. Consider alternative diagnoses for the coagulopathy (liver failure, vitamin K deficiency, massive transfusion dilutional coagulopathy, drug-induced coagulopathy). Critical context: the ISTH score is only valid in patients with an underlying condition known to cause DIC. A score of 5 in a healthy outpatient without a DIC-precipitating condition is not meaningful — this score requires a clinical context such as sepsis, trauma, obstetric complication, leukemia, or metastatic cancer.
Two major diagnostic challenges: (1) Differentiating DIC from liver failure — both cause prolonged PT, elevated D-dimer, and thrombocytopenia. The key distinguishing test is **Factor VIII activity**: Factor VIII is synthesized in vascular endothelium (not the liver) and is consumed in DIC, so DIC reduces Factor VIII levels. Liver failure spares Factor VIII (often elevated due to inflammation). A low Factor VIII in a patient with elevated PT + low fibrinogen + elevated D-dimer strongly supports DIC over pure liver disease. (2) DIC in pregnancy: baseline fibrinogen is elevated (typically 4–6 g/L in the 3rd trimester vs normal 2–4 g/L). A fibrinogen of 2.5 g/L, which appears 'normal' by standard reference ranges, is actually significantly consumed in a pregnant patient. DIC in pregnancy may score falsely low on fibrinogen component — use trend (falling fibrinogen) rather than absolute value. Transfusion therapy decisions in actively bleeding DIC patients: **Platelet transfusion** for count <20–50 × 10⁹/L with active bleeding, or <50k before invasive procedures. **Fresh frozen plasma (FFP)** for PT/INR correction in actively bleeding patients (target INR <1.5–2.0); dose 10–15 mL/kg initially. **Cryoprecipitate** for fibrinogen <1.5 g/L with active bleeding; each unit raises fibrinogen by approximately 0.5–1.0 g/L. **Do NOT transfuse prophylactically** without active bleeding — transfusion in non-bleeding DIC patients can potentially worsen coagulation activation. Heparin remains controversial in DIC; it may be considered in clot-dominant DIC (purpura fulminans, arterial thrombosis) but is generally avoided in bleeding-dominant DIC.
Intensivists and critical care nurses
Sepsis is the most common precipitant of DIC, occurring in 35–50% of severe sepsis cases. Apply the ISTH DIC score at ICU admission and every 6–12 hours in critically ill septic patients with coagulation abnormalities. A rising ISTH score despite adequate source control and antibiotics suggests uncontrolled sepsis with progressive coagulopathy, warranting reassessment of source control adequacy. Integrate ISTH DIC scores with SOFA scores to track multi-organ dysfunction — worsening DIC typically parallels deteriorating SOFA scores in septic patients.
Obstetricians, midwives, and maternal-fetal medicine specialists
Obstetric DIC is a feared complication of placental abruption, amniotic fluid embolism, retained dead fetus, and severe preeclampsia/HELLP syndrome. These conditions can cause catastrophic coagulopathy within minutes to hours. Use the ISTH DIC score to rapidly assess coagulation status, remembering that fibrinogen baseline is elevated in pregnancy (4–6 g/L in 3rd trimester) — a fibrinogen of 2.5 g/L represents significant DIC even if the score assigns it 0 points for fibrinogen. Trigger massive transfusion protocols early and coordinate with hematology and blood bank.
Hematologists and leukemia specialists
Acute promyelocytic leukemia (APL, AML-M3) classically causes a DIC-like coagulopathy through release of tissue factor and fibrinolytic mediators from leukemic cells. APL DIC may present with a fibrinogenolysis-dominant pattern (extremely low fibrinogen, elevated D-dimer) rather than classic consumptive DIC. Use the ISTH DIC score to quantify coagulopathy severity and guide transfusion support during ATRA (all-trans retinoic acid) induction therapy, which can temporarily worsen DIC before resolving it. Serial daily ISTH scoring until coagulopathy resolves is standard in APL management.
Trauma surgeons and emergency medicine physicians
Severe trauma (massive hemorrhage, traumatic brain injury, crush injuries) causes DIC through release of tissue factor, endothelial damage, and hypothermia-coagulopathy. Trauma-induced coagulopathy (TIC) often manifests early (within 30–60 minutes of injury) and is associated with dramatically increased mortality. Calculate the ISTH DIC score on arrival and after initial resuscitation. High ISTH scores predict need for massive transfusion protocols and should trigger early coagulation-directed resuscitation (balanced 1:1:1 ratio of red cells, FFP, and platelets or whole blood transfusion).
Hepatologists, gastroenterologists, and hospitalists
Liver failure and DIC both cause prolonged PT, thrombocytopenia, elevated D-dimer, and low fibrinogen — making differentiation clinically challenging. The ISTH DIC score, combined with Factor VIII activity, helps differentiate. In liver failure, Factor VIII is normal or elevated (not synthesized by hepatocytes — synthesized by endothelium); in DIC, Factor VIII is consumed and low. Additional clues: schistocytes on blood smear suggest DIC-associated microangiopathy; serial PT/fibrinogen trends (rapidly worsening in DIC, more stable in liver failure); underlying clinical context (sepsis vs cirrhosis).
The most important principle in DIC management is that correcting coagulation parameters (transfusing FFP, platelets, cryoprecipitate) is purely supportive — DIC will not resolve until the underlying precipitant is controlled. If the patient has septic DIC, the coagulopathy will not improve without adequate source control (drainage of abscess, removal of infected device) and effective antibiotics. If obstetric DIC, delivery of the fetus and placenta is the definitive treatment. If leukemia-associated DIC (especially APL), induction chemotherapy with ATRA to differentiate leukemic cells is required. Transfusion support buys time for the underlying treatment to work; it does not treat DIC.
Fibrinogen is synthesized in the liver and behaves as an acute-phase protein — its levels rise with inflammation. A patient with early DIC may have a 'normal' fibrinogen of 3.0 g/L (above the 1 g/L threshold that scores a DIC point), yet this value may represent a significant drop from their inflammatory baseline of 5.0 g/L. Serial measurement is critical: a fibrinogen falling from 4.5 → 3.0 → 1.8 → 0.9 g/L over 24–48 hours is diagnostic of evolving DIC even if the first two values appear 'normal.' This is especially relevant in pregnancy (baseline fibrinogen 4–6 g/L in 3rd trimester) and in critically ill patients with chronic inflammatory states. Calculate the rate of fibrinogen decline, not just the absolute value.
A common error is transfusing FFP, cryoprecipitate, or platelets in non-bleeding DIC patients simply because the labs are abnormal. Prophylactic transfusion in DIC without active bleeding has not been shown to improve outcomes and may potentially worsen coagulation activation by providing substrates (fibrinogen, clotting factors) that fuel the ongoing thrombosis. Reserve transfusion for: (1) actively bleeding patients, (2) patients requiring invasive procedures with high bleeding risk, or (3) patients with severe thrombocytopenia (<20k) at very high hemorrhage risk. Document clearly: 'ISTH DIC score 6. No active bleeding at this time. Serial monitoring every 6 hours. Will transfuse if active hemorrhage develops or if pre-procedure.'
This is one of the most diagnostically powerful tests in suspected DIC with concurrent liver disease. Factor VIII is synthesized by vascular endothelium (not hepatocytes) and is an acute-phase reactant. In DIC, Factor VIII is consumed by thrombin activation and is LOW. In liver failure, Factor VIII is preserved (often elevated as an acute-phase response) because the endothelium is not affected. A Factor VIII level <50% of normal in a patient with coagulopathy strongly supports DIC over isolated liver failure. Caveats: Factor VIII is elevated in von Willebrand disease (because VWF protects Factor VIII from degradation), hemophilia A will have low Factor VIII at baseline, and combined DIC + liver failure can make interpretation complex.
Acute promyelocytic leukemia (APL) is a hematologic emergency that can present with a coagulopathy pattern distinct from classic sepsis-associated DIC. APL cells release profibrinolytic factors (annexin A2, plasminogen activator) that cause primary fibrinogenolysis (direct breakdown of fibrinogen without fibrin clot formation). The result: markedly low fibrinogen, elevated D-dimer/FDPs, but less prominent thrombocytopenia and PT prolongation than expected in consumptive DIC. ISTH DIC scores may be high due to elevated fibrin markers and low fibrinogen but relatively preserved platelet count. If APL is suspected (new blast-predominant leukocytosis with coagulopathy, especially in a young patient), do NOT wait for definitive diagnosis before starting ATRA — empiric initiation of ATRA is life-saving and should begin immediately, before bone marrow biopsy results are available.
In septic DIC, calculate the ISTH DIC score every 6–12 hours during the acute phase. An improving score (e.g., 6 → 5 → 4 → 3 over 24–48 hours) confirms that source control is effective and systemic coagulation activation is resolving. A plateau or rising score despite appropriate antibiotics and pressors suggests inadequate source control — is there an undrained abscess? Inadequate antibiotic coverage? Fungal co-infection? Occult endocarditis? Use the serial DIC score as a trigger to reassess source control adequacy. A score that returns to <3 correlates with resolution of overt DIC and can guide de-escalation of coagulation support.
Therapeutic heparin in DIC is generally avoided in most clinical scenarios due to risk of worsening hemorrhage. However, there are specific contexts where heparin or anticoagulation may be beneficial: purpura fulminans (massive microvascular thrombosis causing skin necrosis and limb ischemia, typically in meningococcemia or protein C/S deficiency), clot-dominant DIC with arterial thrombosis or venous gangrene, and DIC associated with aortic aneurysm or giant hemangioma (Kasabach-Merritt syndrome). In these clot-dominant presentations, the risk of thrombosis exceeds bleeding risk and anticoagulation with UFH at prophylactic to therapeutic doses may be considered. Consult hematology for complex DIC cases requiring anticoagulation decisions.
Pregnant women have significantly elevated baseline fibrinogen (3rd trimester: 4.0–6.0 g/L, compared to normal 2–4 g/L in non-pregnant adults). In obstetric DIC (placental abruption, amniotic fluid embolism, HELLP syndrome), fibrinogen is rapidly consumed — but the absolute value may still appear 'normal' (e.g., 2.5 g/L) while representing a dramatic 50–60% drop from baseline. In obstetric emergencies, a fibrinogen <2.0 g/L should trigger urgent cryoprecipitate transfusion and massive transfusion protocol activation, even if the standard ISTH threshold of <1.0 g/L has not been reached. Many obstetric DIC guidelines use the higher threshold of <2.0 g/L as the trigger for cryoprecipitate in pregnancy.
Request a peripheral blood smear review when DIC is suspected. The presence of schistocytes (fragmented red blood cells — helmet cells, triangular forms, teardrop shapes) provides morphological evidence of microangiopathic hemolytic anemia (MAHA), confirming mechanical shearing of erythrocytes by fibrin strands in the microcirculation — a hallmark of DIC and other thrombotic microangiopathies (TTP, HUS, HELLP). The ISTH DIC score does not include schistocytes, but their presence corroborates the diagnosis. Conversely, the absence of schistocytes in a patient with high ISTH score makes fibrinolysis-dominant DIC (as in APL) or liver failure more likely. Always request blood smear interpretation from hematopathology in complex coagulopathy cases.
Actively bleeding DIC patients often require large volumes of FFP (10–15 mL/kg per dose = 700–1,050 mL for a 70 kg patient), cryoprecipitate, and platelets. This creates significant volume overload risk, especially in patients with cardiac dysfunction, renal failure, or older age — transfusion-associated circulatory overload (TACO) can precipitate or worsen respiratory failure. Consider: (1) Prothrombin complex concentrate (PCC) as an alternative to FFP for factor replacement — PCC provides concentrated clotting factors in 20–40 mL volume (vs 200–250 mL per unit FFP). (2) Tranexamic acid (TXA) in fibrinolysis-dominant DIC to reduce fibrinolytic activity and decrease transfusion requirements. (3) Point-of-care coagulation testing (thromboelastography/TEG, ROTEM) to guide targeted component therapy rather than empiric transfusion bundles.
ISTH DIC scoring system was developed by Taylor et al. (Thromb Haemost 2001). Sensitivity 91–93% and specificity 97–98% for overt DIC in appropriate clinical settings. ISTH-SSC guidelines on DIC management were updated 2013. Differential from liver disease using factor VIII: DIC reduces all coagulation factors including VIII; liver disease spares VIII (not produced in liver). ASH 2023 DIC practice guidelines recommend serial scoring.
Higher ISTH DIC scores indicate greater likelihood of overt DIC when combined with an underlying clinical condition known to trigger systemic coagulation activation. Score ≥5 = overt DIC (requires urgent treatment of precipitant and transfusion support for active bleeding). Score 3–4 = non-overt DIC (serial monitoring every 6–8 hours). Score <3 = DIC unlikely.
Use this score in suspected DIC contexts such as sepsis, trauma, obstetric emergencies, or advanced malignancy with coagulation abnormalities. Always interpret in clinical context — the score is only meaningful in patients with a known DIC precipitant. Repeat every 6–12 hours to track treatment response.
Lab thresholds and fibrin-marker interpretation vary by institution. The score must be interpreted with clinical context and serial trends. D-dimer and PT are confounded by anticoagulation therapy (heparin, warfarin, DOACs). Fibrinogen may be falsely 'normal' in inflammatory states or pregnancy. The score does not differentiate DIC from other microangiopathic processes (TTP, HUS) that require different management.
For related assessments, see 4T Score (HIT), SOFA Score and qSOFA Score.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Score HIT pretest probability with the validated 4T tool. Score ≤3: >99% NPV — HIT unlikely. Score ≥4: stop heparin and switch anticoagulants. Free clinical calculator.
OpenEmergencyCalculate the SOFA score to assess organ dysfunction severity in critically ill patients. Scores range from 0 to 24 across six organ systems.
OpenEmergencyCalculate qSOFA bedside sepsis risk score. A score of 2 or more (altered mentation, RR ≥22, SBP ≤100) flags high-risk infection requiring urgent evaluation.
OpenEmergencyCalculate NEWS2 from vital signs and mental status to detect acute clinical deterioration and guide escalation urgency.
Open